Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
Top Cited Papers
- 1 July 2017
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 72 (1), 34-42
- https://doi.org/10.1016/j.eururo.2017.02.023
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerNew England Journal of Medicine, 2016
- Familial Risk and Heritability of Cancer Among Twins in Nordic CountriesJAMA, 2016
- Plasma AR and abiraterone-resistant prostate cancerScience Translational Medicine, 2015
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerEuropean Urology, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBritish Journal of Cancer, 2011
- Systematic Population-Based Assessment of Cancer Risk in First-Degree Relatives of Cancer ProbandsJNCI Journal of the National Cancer Institute, 1994